Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05671991 · ClinicalTrials.gov registry record · Phase 4

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

A Phase 4 study of End Stage Renal Disease on Dialysis, sponsored by Yale University.

Recruiting
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT05671991 is a Phase 4 study of End Stage Renal Disease on Dialysis that is actively recruiting participants, run by Yale University. The registered enrollment target is 30 participants, below the 74-participant average among 9 other End Stage Renal Disease on Dialysis trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05671991, a Phase 4 study of End Stage Renal Disease on Dialysis, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.

Conditions Studied

End Stage Renal Disease on Dialysis

Interventions

  • DRUG Empagliflozin 10 MG
  • DRUG Empagliflozin 25 mg vs Placebo

Study Locations (1)

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-03-01
Est. Completion 2026-06-30
Phase Phase 4

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05671991

The ClinicalTrials.gov registry entry for NCT05671991 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 9 other End Stage Renal Disease on Dialysis trials with a reported enrollment target (59% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with End Stage Renal Disease on Dialysis appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin 10 MG is the first listed.

NCT05671991 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05671991 about?

NCT05671991 is a clinical study titled "Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease". The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, w...

What is the current status of trial NCT05671991?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-03-01. Estimated completion is 2026-06-30.

What conditions does trial NCT05671991 study?

This clinical trial studies the following conditions: End Stage Renal Disease on Dialysis.

What interventions are being tested in trial NCT05671991?

The interventions under investigation include: Empagliflozin 10 MG (DRUG), Empagliflozin 25 mg vs Placebo (DRUG).

Who is sponsoring clinical trial NCT05671991?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05671991 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for End Stage Renal Disease on Dialysis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

End Stage Renal Disease on Dialysis

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.